Shoreline Biosciences Revenue and Competitors

Claim your profile

Location

#3425

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Shoreline Biosciences's estimated annual revenue is currently $14.7M per year.(i)
  • Shoreline Biosciences's estimated revenue per employee is $188,782
  • Shoreline Biosciences's total funding is $186M.

Employee Data

  • Shoreline Biosciences has 78 Employees.(i)
  • Shoreline Biosciences grew their employee count by 42% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.8M512%$53MN/A
#2
$29.6M125-12%$110MN/A
#3
$0.4M60%N/AN/A
#4
$0.8M12140%N/AN/A
#5
$0.5M70%N/AN/A
#6
$0.4M25717%$236.7MN/A
#7
$21.5M114-23%$160MN/A
#8
$0.6M1011%N/AN/A
#9
$3.7M2111%N/AN/A
#10
N/A60150%N/AN/A
Add Company

Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.

keywords:N/A

$186M

Total Funding

78

Number of Employees

$14.7M

Revenue (est)

42%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Shoreline Biosciences News

2022-04-13 - Shoreline Biosciences Presents Data at AACR 2022 ...

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells...

2022-04-06 - Shoreline Biosciences Presents Data at AACR 2022 ...

Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells.

2022-03-22 - SHORELINE BIOSCIENCES ANNOUNCES ORAL ...

SHORELINE BIOSCIENCES ANNOUNCES ORAL PRESENTATION on ipsc-derived NK cell (iNK) platform AT INNATE KILLER SUMMIT meeting 2022.

2021-11-02 - Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies

SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapie ...

2021-11-02 - Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies

Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biotechnology co ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.7M78-2%N/A
#2
$26.8M783%N/A
#3
$11.9M79-2%N/A
#4
$15.7M8363%$76.5M
#5
$12.9M8615%N/A